Ophthalmology

Inconsistent estimates of self-reported impairment across surveys could impact surveillance on the size of the population with vision problems.

These data pointed to a low risk of persistent IOP increases of intravitreous 0.1-mL injection volumes administered for 1 year in eyes with GA.

A first-time trial presented at ADA 2024 found the common cholesterol-lowering drug halts vision loss in patients with diabetic eye disease.

A panel of ophthalmologists discuss how retinal disease management has evolved in the past decade and continues to change with advancements in diagnostics and therapies.

Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.

Michael Freeman joins Veeral Sheth, MD to discuss the history of Ocutrx, its OcuLenz and OR-Bot products, and what he envisions in the next decade at the company.

Improvements in multiple sign efficacy endpoints were observed in the full study population, with more pronounced effects in the TNFR1 genetic biomarker population.

This month-in-review features an exclusive interview with Srinivas R. Sadda, MD, and promising data from studies on geographic atrophy, diabetic macular ischemia, diabetic retinopathy, and AMD.

Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.

Experts discuss strategies for making dry eye care an appealing practice option for optometry students and supporting their success in this specialized field.

A panel of ophthalmologists discuss how retinal disease management has evolved in the past decade and continues to change with advancements in diagnostics and therapies.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.

Aflibercept 8 mg exhibited clinically meaningful visual, anatomic improvements at Week 48 in patients with DME regardless of baseline visual acuity.

Pre-dose IOP outcomes in eyes with DME receiving intravitreal aflibercept 8 mg or 2 mg were comparable and remained stable through Week 48.

At the end of ARVO 2024, Srinivas R. Sadda, MD, became the organization's president for the 2024-2025 year. He spoke to HCPLive about his expectations for the next year in eye care.

Factors, including social deprivation and race, significantly affected visit adherence for patients with nAMD across a large healthcare system.

At ARVO 2024, Nazlee Zebardast, MD, MSc describes the value of a polygenic risk score to predict the onset of primary open-angle glaucoma.

A higher dietary intake of several nutrients was strongly associated with slower progression toward the central macula in eyes with non-central GA.

Disease characteristics in wet AMD at baseline were not linked to aflibercept 8 mg dosing interval extensions in the phase 3 PULSAR trial at 96 weeks.

Retina specialists and an AI screening tool trained to measure geographic atrophy agreed in a majority of cases, potentially expediting clinical trial enrollment and increasing consistency in measuring the disease.

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

The phase 2 trial failed to show improvement of ≥2-DRSS levels with the vorolanib intravitreal insert in patients with non-proliferative diabetic retinopathy.

BI 764524 was well tolerated following intravitreal administration of single and multiple doses in the phase 1/2a trial, with signs pointing to early efficacy.

A nutritional supplement significantly improved the signs and symptoms of dry eye, including tear production and reduced ocular surface damage.